Corbus Pharmaceuticals Holdings (CRBP) Total Current Liabilities (2013 - 2025)
Corbus Pharmaceuticals Holdings (CRBP) posted quarterly Total Current Liabilities of $20.7 million for Q4 2025, up 75.09% year-over-year from $11.8 million in Q4 2024, and up 21.29% quarter-over-quarter from $17.1 million in Q3 2025.
Corbus Pharmaceuticals Holdings (CRBP) Total Current Liabilities (2013 - 2025) Analysis & Trends
Corbus Pharmaceuticals Holdings' Total Current Liabilities history runs 13 years deep, the most recent figure standing at $20.7 million for Q4 2025.
- In Q4 2025, Total Current Liabilities rose 75.09% year-over-year to $20.7 million; the TTM figure through Dec 2025 stood at $20.7 million (up 75.09% YoY), while the FY2025 annual figure was $20.7 million, up 75.09% from the prior year.
- Total Current Liabilities for Q4 2025 stood at $20.7 million, up from $17.1 million in the prior quarter.
- The five-year high for Total Current Liabilities was $31.9 million in Q4 2023, with the low at $11.6 million in Q1 2025.
- The 5-year median for Total Current Liabilities is $17.0 million (2021), against an average of $18.4 million.
- The sharpest annual moves came in 2023 and 2024: Total Current Liabilities surged 152.33% in 2023, then plunged 63.14% in 2024.
- Corbus Pharmaceuticals Holdings' Total Current Liabilities stood at $17.0 million in 2021, then retreated by 25.68% to $12.6 million in 2022, then jumped by 152.33% to $31.9 million in 2023, then slumped by 62.95% to $11.8 million in 2024, then soared by 75.09% to $20.7 million in 2025.
- Business Quant data shows CRBP's Total Current Liabilities at $20.7 million in Q4 2025, $17.1 million in Q3 2025, and $13.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.51 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 438.74 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 630.93 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 2.49 Bn |
| 10 | Corbus Pharmaceuticals Holdings | 121.72 Mn | -41.55 Mn | - | 20.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 20.69 Mn |
| Sep 30, 2025 | 17.06 Mn |
| Jun 30, 2025 | 13.33 Mn |
| Mar 31, 2025 | 11.62 Mn |
| Dec 31, 2024 | 11.82 Mn |
| Sep 30, 2024 | 11.63 Mn |
| Jun 30, 2024 | 23.98 Mn |
| Mar 31, 2024 | 25.92 Mn |
| Dec 31, 2023 | 31.89 Mn |
| Sep 30, 2023 | 31.54 Mn |
| Jun 30, 2023 | 16.39 Mn |
| Mar 31, 2023 | 14.36 Mn |
| Dec 31, 2022 | 12.64 Mn |
| Sep 30, 2022 | 17.47 Mn |
| Jun 30, 2022 | 15.63 Mn |
| Mar 31, 2022 | 15.12 Mn |
| Dec 31, 2021 | 17.01 Mn |
| Sep 30, 2021 | 17.14 Mn |
| Jun 30, 2021 | 18.74 Mn |
| Mar 31, 2021 | 23.61 Mn |